See details
|
Biomarkers in Late Stage Clinical Trials: Applications, opportunities and activities of leading players
Biomarkers reduce the attrition rate of late stage clinical trials by assessing drug potential in terms of efficacy and toxicity at the early stages of the clinical development. Thus, biomarkers significantly increase productivity, lower the cost and duration of the clinical trial, and help researchers complete drug development process at a faster pace.
This report reviews various biomarker technologies and therapy area applications. Market drivers and restraints are viewed in the context of biomarker activity of leading innovator companies as well as contract research organizations.
Our price: $ 3,835.00
|
See details
|
Delivering Opportunities in the Inhalable Drugs Market: Innovative formulations and devices
This report evaluates the current state of the inhaled market, examining the currently limited impact of inhaled formulations in non-respiratory segments and the dominance of the respiratory market, a major market segment, by inhaled formulations. It examines the formulations currently in development for both non-respiratory and respiratory indications as well as summarizing the inhaled formulations of new chemical entities being developed for the treatment of respiratory disease.
Our price: $ 3,835.00
|
See details
|
Innovations in Injectables: Current and emerging technologies to improve drug delivery
This report evaluates the current and evolving technologies used for injectable drug delivery, the key therapuetic areas, the barriers and driving forces for this market, the competitive landscape is analysed according the technology type, and key pipeline companies and products are examined. Leading companies in the injectable drug delivery market are also profiled.
Our price: $ 3,835.00
|
See details
|
Opportunities in Emerging Pharma Markets: Strategies for optimizing growth in key regions and therapeutic areas
The flurry of recent industry acquisitions and alliances focused on product portfolios and distribution networks in the Emerging Markets underscores the attractiveness of these areas for the Pharmaceutical industry. This report outlines many of these recent industry alliances, by companies including Pfizer, GSK, Novartis, Abbott, Daiichi Sankyo and others. Many of these alliances have been focused on obtaining the Pharmaceuticals, Generics, Vaccines, OTC’s, Hepatitis and HIV/AIDS agents and Biosimilars appropriate for the Emerging markets. Other companies still seeking alliances are identified, as well as those that appear to be potential generic and Biosimilar supply partners.
This report provides market forecasts for the major Emerging markets, by IMS and by key industry players. It also outlines the opportunities and challenges presented by market, the major companies focusing...
|
See details
|
Opportunities in Orphan Drugs: Strategies for developing maximum returns from niche indications
Orphan drugs present opportunities to pharma companies looking to move into more niche indications and away from mass market indications that have very low levels of clinical unmet need. Although there are many successful orphan drugs that have made large profits for their developers (Gleevec, NovoSeven etc) the development of these products must be approached carefully. This report uses a mixture of case studies and data from secondary sources to elucidate the key issues in the development of orphan drugs and ways to navigate them.
Our price: $ 3,835.00
|
See details
|
The Future of Cardiovascular Diagnostics: Impact of technological advances on growth opportunities and future market outlook
Cardiovascular disease (CVD) is one of the leading causes of death in the developed world, accounting for around a third of all deaths. It remains a tremendous medical and cost burden on society. The identification and application of novel cardio biomarkers has helped cardiologists to stratify high risk patients whilst the advances in diagnostic imaging has lead to improvements in the speed and resolution of images, increasing its clinical utility in the detection, diagnosis and treatment of CVD whilst minimizing the need for invasive procedures. In addition, diagnostic imaging provides cardiologists with detailed anatomical (CT, MRI, US), metabolic and functional (nuclear imaging, fMRI) information upon which an accurate diagnosis an be made. Currently no single imaging test is superior to all the others and a variety of imaging modalities may be used to diagnose CVD.
Our price: $ 3,835.00
|
See details
|
The Future of the Biologicals Market: Market overview, innovations and company profiles
Biopharmaceutical products are the key to the future of the pharmaceutical market. Even before the market stagnation seen in 2009 due to the recession, conventional pharmaceuticals were facing drastic consequences from the loss of patent cover for many blockbusters, and the continued failure of the R&D departments in big pharma to produce replacement candidates.
Although the conventional, small-molecule segment of the market will continue to hold a larger share, their growth is expected to be in low single figures, while biopharma products are forecast to grow at rates up to 10% per annum.
This report analyses the three main components of the biopharma market – monoclonal antibodies, therapeutic proteins and vaccines – to show why these groups have such a positive future. It provides the most up-to-date discussion of the whole biopharma market and explores new clinical indicat...
|
|
|
